Literature DB >> 28385354

Triple therapy for symptomatic patients with COPD.

Leonardo M Fabbri1, Sara Roversi2, Bianca Beghé2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28385354     DOI： 10.1016/S0140-6736(17)30567-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.

Authors:  Dave Singh; Massimo Corradi; Monica Spinola; Alberto Papi; Omar S Usmani; Mario Scuri; Stefano Petruzzelli; Jørgen Vestbo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-10-06

2.  COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.

Authors:  Wilhelmine Meeraus; Robert Wood; Rafal Jakubanis; Tim Holbrook; Geoffray Bizouard; Johanna Despres; Camille Correia Da Silva; Gaelle Nachbaur; Sarah H Landis; Yogesh Punekar; Bernard Aguilaniu; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-12-18

3.  A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD.

Authors:  Courtney Crim; Mark Gotfried; Selwyn Spangenthal; Michael Watkins; Amanda Emmett; Catriona Crawford; Charlotte Baidoo; Ramiro Castro-Santamaria
Journal:  BMC Pulm Med       Date:  2020-05-04       Impact factor: 3.317

Review 4.  Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Pulm Ther       Date:  2019-11-02

5.  In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients.

Authors:  Javier Milara; Sonia Contreras; Alfredo de Diego; Marta Calbet; Mònica Aparici; Esteban Morcillo; Montserrat Miralpeix; Julio Cortijo
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.